ImQuest Reports Positive Results of Anti-HIV Drug Candidates
Posted on: Friday, 18 April 2008, 09:00 CDT
ImQuest Life Sciences has presented new results on the development of their lead anti-HIV therapeutic development candidate, IQP-0410, and lead topical microbicide development candidate, IQP-0528.
ImQuest studies have demonstrated that each of these highly novel pyrimidinedione inhibitors act by two distinct mechanisms of action, preventing the entry of HIV into human cells and inhibiting the activity of a key HIV enzyme, reverse transcriptase.
The studies on IQP-0410 showed that the compound targets a newly defined conformational cell surface target formed upon attachment of the virus to prevent the entry of HIV into the cells. The ImQuest team also demonstrated that IQP- 0410 was highly effective against multi-drug resistant HIV, especially viruses derived from patients treated extensively with protease inhibitors.
Robert Buckheit, Jr., executive vice president and chief scientific officer of ImQuest, said: "Our results clearly indicate that the pyrimidinediones represent a completely new class of HIV inhibitor that may be of great benefit to the prevention of HIV infection as a topical microbicide, the therapeutic treatment of primary HIV infection, as well as a salvage therapy for patients failing current drug regimens."
Source: Datamonitor
Related Articles
- Most Pharmaceutical Companies Receive Poor Grades on HIV/AIDS Drug Development Innovation, According to AIDS Treatment Activist Coalition Report Card
- ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
- Possible New HIV Treatment is Developed
- Research!America Honors Univ. Of Chicago Economists for Study Showing Economic Impact of HIV/AIDS Drug Development
- Targeted Genetics Enters into New Agreement With the International Aids Vaccine Initiative to Support Its Ongoing HIV/AIDS Vaccine Development Program
- GeoVax Launches Clinical Human Trials for Its HIV/AIDS Vaccine Developed at GeoVax Inc., Emory University, NIH and the CDC
- ImQuest Pharmaceuticals Announces Final Stage Development of Pyrimidinedione Topical Microbicide to Prevent Transmission of HIV in the Developing World
- White House Partnership on Pediatric HIV/AIDS a Positive Development, Says Global AIDS Alliance
- Merck & Co Reduces Price of HIV Drug in Developing Countries
- Roche and Trimeris Select Two HIV Candidates for Development
 |
 |
User Comments (0)
RSS Feeds